CompletedPhase 3

Pentoxifylline Treatment in Acute Pancreatitis (AP)

United States83 participantsStarted 2015-05

Plain-language summary

The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria * Enrollment within 72 hours of diagnosis of acute pancreatitis (AP) * Ability to give informed consent or a Legal Adult Representative (LAR) able to give informed consent for subject when needed as defined buy LAR use guidelines. * Adult subjects of age ≥18 years. Exclusion Criteria: * Moderate or severe congestive heart failure * History of seizure disorders or demyelinating disease * Nursing mothers * Pregnancy * History of prior tuberculosis or risk factors for tuberculosis * Evidence of non- corticosteroid immunosuppression (such as malignancy, chronic renal failure, chemotherapy within 60 days, and HIV) * Evidence of active hemorrhage * Paralytic ileus with severe nausea and vomiting

What they're measuring

Change in C-reactive Protein (C-RP) From Admission Baseline at One Week.

Timeframe: Admission (baseline), day 5

Change in Tumor Necrosis Factor-alpha (TNF-a) Levels From Admission Baseline at One Week.

Timeframe: Admission (baseline), day 5

Change in Interleukin-6 (IL-6) Levels From Admission Baseline at One Week.

Timeframe: Admission (baseline), day 5

Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.

Timeframe: Admission (baseline), day 5

Trial details

NCT IDNCT02487225

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-04-30

Results submitted2018-09-25

View on ClinicalTrials.gov More Acute Pancreatitis (AP) trials